The Chosun Ilbo on MSN

Vanoglipel emerges as dual MASH-diabetes treatment with combination potential

Following the success of obesity treatments, global pharmaceutical and biotech industries are increasingly focusing on the ...
The Manila Times

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as 'Ribo'), in ...
pharmaphorum

EMA panel endorses AI for MASH clinical trials

Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...
Medical Xpress

MASH discovery redefines subtypes with distinct risks: Findings could shape future of fatty liver disease treatment

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...